Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
06.03. | THERALINK TECHNOLOGIES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
20.02. | THERALINK TECHNOLOGIES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
15.02. | THERALINK TECHNOLOGIES, INC. - 10-K/A, Annual Report | 1 | SEC Filings | ||
15.02. | THERALINK TECHNOLOGIES, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
29.12.23 | THERALINK TECHNOLOGIES, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
18.12.23 | Theralink Technologies, Inc.: Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates | 270 | GlobeNewswire (Europe) | Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse phase... ► Artikel lesen | |
28.11.23 | THERALINK TECHNOLOGIES, INC. - 8-K, Current Report | - | SEC Filings | ||
13.11.23 | Theralink Technologies, Inc.: Theralink and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4 | 137 | GlobeNewswire (Europe) | Golden, Colorado & Nashville, Tennessee, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink"), a precision oncology company with its exclusive commercial RPPA (reverse... ► Artikel lesen | |
03.11.23 | Theralink Technologies, Inc.: Theralink Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute's Molecular Tumor Board | 191 | GlobeNewswire (Europe) | Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink"), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array)... ► Artikel lesen | |
04.10.23 | Theralink Technologies, Inc.: Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023 | 416 | GlobeNewswire (Europe) | Golden, Colorado, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein and protein assay... ► Artikel lesen | |
27.06.23 | Theralink Technologies, Inc.: Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer | 300 | GlobeNewswire (Europe) | Golden, Colorado, June 27, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein and protein assay... ► Artikel lesen | |
23.05.23 | IMAC Holdings, Inc.: Theralink Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company | 478 | GlobeNewswire (Europe) | Theralink's patented technology is helping to solve a significant problem in cancer treatment by providing game changing technology that can predict FDA-approved drugs that may be effective in each... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,235 | +0,82 % | Evotec: War dieser Crash berechtigt? | Auf den ersten Blick wirkten die Ergebnisse des Vorjahres, die Evotec am Mittwochmorgen vorlegte, zwar nicht gerade gut, aber sie hätten nie und nimmer die Basis für einen Crash von 32 Prozent sein... ► Artikel lesen | |
QIAGEN | 38,760 | +2,16 % | Biotech Report: Sektor fester - Evotec und Qiagen können zulegen | (shareribs.com) Frankfurt / New York 22.04.2024 - Biotech-Aktien verzeichneten zum Wochenauftakt im deutschen Handel Kursgewinne. Gesucht waren unter anderem Evotec und Qiagen. Auch an der Wall Street... ► Artikel lesen | |
CULLINAN THERAPEUTICS | 25,300 | +31,43 % | PEGY, CGEM and IFBD among mid-day movers | ||
RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
CABALETTA BIO | 11,010 | -9,61 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 45,530 | +3,01 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
IMMUNOVANT | 27,170 | -2,09 % | Should You Hold Immunovant (IMVT)? | ||
KEROS THERAPEUTICS | 57,86 | +6,77 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 24,360 | +2,22 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
DYNE THERAPEUTICS | 24,730 | +4,37 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
ARCELLX | 51,92 | +1,05 % | Should You Be Bullish on Arcellx (ACLX)? | ||
DAY ONE BIOPHARMACEUTICALS | 14,920 | +12,94 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
BIONTECH | 82,40 | +2,11 % | Besser als BioNTech oder Moderna? Diese Aktie schlägt den Markt seit Jahren - kann sie das wieder? | Sie ist etabliert, zahlt eine Dividende und liefert schon lange eine überdurchschnittliche Performance ab. Diese Biotech-Aktie sollten Anleger auf dem Schirm haben. Das US-Biotech-Unternehmen Amgen... ► Artikel lesen | |
KYMERA THERAPEUTICS | 33,370 | +0,06 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
NUVALENT | 66,86 | +1,20 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen |